Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

527

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals